p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma
Open Access
- 14 February 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (4), 1377-1388
- https://doi.org/10.1158/0008-5472.can-09-2598
Abstract
MYCN amplification occurs in ∼25% of neuroblastomas, where it is associated with rapid tumor progression and poor prognosis. MYCN plays a paradoxical role in driving cellular proliferation and inducing apoptosis. Based on observations of nuclear p53 accumulation in neuroblastoma, we hypothesized that MYCN may regulate p53 in this setting. Immunohistochemical analysis of 82 neuroblastoma tumors showed an association of high p53 expression with MYCN expression and amplification. In a panel of 5 MYCN-amplified and 5 nonamplified neuroblastoma cell lines, and also in the Tet21N-regulatable MYCN expression system, we further documented a correlation between the expression of MYCN and p53. In MYCN-amplified neuroblastoma cell lines, MYCN knockdown decreased p53 expression. In Tet21N MYCN+ cells, higher levels of p53 transcription, mRNA, and protein were observed relative to Tet21N MYCN- cells. In chromatin immunoprecipitation and reporter gene assays, MYCN bound directly to a Myc E-Box DNA binding motif located close to the transcriptional start site within the p53 promoter, where it could initiate transcription. E-Box mutation decreased MYCN-driven transcriptional activation. Microarray analysis of Tet21N MYCN+/− cells identified several p53-regulated genes that were upregulated in the presence of MYCN, including MDM2 and PUMA, the levels of which were reduced by MYCN knockdown. We concluded that MYCN transcriptionally upregulates p53 in neuroblastoma and uses p53 to mediate a key mechanism of apoptosis. Cancer Res; 70(4); 1377–88Keywords
Other Versions
This publication has 48 references indexed in Scilit:
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group StudyJournal of Clinical Oncology, 2009
- Hematopoietic Stem Cell Function and Survival Depend on c-Myc and N-Myc ActivityCell Stem Cell, 2008
- Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomasGenome Biology, 2008
- Histological profile of tumours from MYCN transgenic miceJournal of Clinical Pathology, 2008
- High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trialThe Lancet Oncology, 2008
- Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumoursApoptosis, 2007
- Suppression of Centrosome Amplification after DNA Damage Depends on p27 AccumulationCancer Research, 2006
- MYCN amplification remains prognostically strong 20 years after its “clinical debut”European Journal Of Cancer, 2004
- N-Myc Shares Cellular Functions with c-MycDNA and Cell Biology, 2000
- MycN sensitizes neuroblastoma cells for drug-induced apoptosisOncogene, 1999